Search for other papers by Jung Soo Lim in
Google Scholar
PubMed
Search for other papers by Seung-Eun Lee in
Google Scholar
PubMed
Search for other papers by Jung Hee Kim in
Google Scholar
PubMed
Search for other papers by Jae Hyeon Kim in
Google Scholar
PubMed
Search for other papers by The Korean Adrenal Gland and Endocrine Hypertension Study Group, Korean Endocrine Society in
Google Scholar
PubMed
p53 and CTNNB1 immunohistochemistry ( 18 ). Recently, progress in genomics has allowed research on the molecular prognostic markers of ACC ( 18 ). Nonetheless, there is a paucity of data on recurrence or survival in Asian patients with ACC
Radiotherapy Department, M. Sklodowska-Curie Institute – Oncology Center, Gliwice Branch, Gliwice, Poland
Search for other papers by Aleksandra Kukulska in
Google Scholar
PubMed
Search for other papers by Jolanta Krajewska in
Google Scholar
PubMed
Search for other papers by Zofia Kolosza in
Google Scholar
PubMed
Search for other papers by Ewa Paliczka-Cieslik in
Google Scholar
PubMed
Search for other papers by Aleksandra Kropinska in
Google Scholar
PubMed
Search for other papers by Agnieszka Pawlaczek in
Google Scholar
PubMed
Search for other papers by Zbigniew Puch in
Google Scholar
PubMed
Search for other papers by Kornelia Ficek in
Google Scholar
PubMed
Search for other papers by Teresa Lisik in
Google Scholar
PubMed
Search for other papers by Dorota Sygula in
Google Scholar
PubMed
Search for other papers by Zbigniew Wygoda in
Google Scholar
PubMed
Search for other papers by Jozef Roskosz in
Google Scholar
PubMed
Search for other papers by Jerzy Wydmanski in
Google Scholar
PubMed
Search for other papers by Barbara Jarzab in
Google Scholar
PubMed
patients longer than 20 years. In this analysis, PFS (progression-free survival) was considered as a time free of local recurrence. The date of cytological confirmation of MTC recurrence in thyroid bed or lymph nodes was the date of the end of PFS. DNA
Search for other papers by Hyunjae Lee in
Google Scholar
PubMed
Search for other papers by Tae-Shin Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Ja-Yoon Gu in
Google Scholar
PubMed
Search for other papers by Mi Ran Yu in
Google Scholar
PubMed
Search for other papers by Seung-Eun Lee in
Google Scholar
PubMed
Search for other papers by Eun Sook Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Hyun Kyung Kim in
Google Scholar
PubMed
malignancies reported shorter recurrence-free survival in patients with a high level of NET markers ( 36 ). Relation of an elevated level of NET markers with poor prognosis in high-grade ovarian cancer has been reported ( 15 ). Similarly, we observed that an
Search for other papers by Prachi Bansal in
Google Scholar
PubMed
Search for other papers by Anurag Lila in
Google Scholar
PubMed
Search for other papers by Manjunath Goroshi in
Google Scholar
PubMed
Search for other papers by Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Nilesh Lomte in
Google Scholar
PubMed
Search for other papers by Kunal Thakkar in
Google Scholar
PubMed
Search for other papers by Atul Goel in
Google Scholar
PubMed
Search for other papers by Abhidha Shah in
Google Scholar
PubMed
Search for other papers by Shilpa Sankhe in
Google Scholar
PubMed
Search for other papers by Naina Goel in
Google Scholar
PubMed
Search for other papers by Neelam Jaguste in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
Search for other papers by Nalini Shah in
Google Scholar
PubMed
recurrence rate was 41% (48/117), and mean time to recurrence was 37.2 ± 27.8 (8–96) months. The Kaplan–Meier analysis for recurrence-free survival is shown in Fig. 1 . Figure 1 Kaplan–Meier curve showing recurrence-free survival of Cushing’s disease
Search for other papers by Filomena Cetani in
Google Scholar
PubMed
Search for other papers by Chiara Banti in
Google Scholar
PubMed
Search for other papers by Elena Pardi in
Google Scholar
PubMed
Search for other papers by Simona Borsari in
Google Scholar
PubMed
Search for other papers by Paolo Viacava in
Google Scholar
PubMed
Search for other papers by Paolo Miccoli in
Google Scholar
PubMed
Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed
Search for other papers by Fulvio Basolo in
Google Scholar
PubMed
Search for other papers by Maria Rosa Pelizzo in
Google Scholar
PubMed
Search for other papers by Massimo Rugge in
Google Scholar
PubMed
Search for other papers by Gianmaria Pennelli in
Google Scholar
PubMed
Search for other papers by Guido Gasparri in
Google Scholar
PubMed
Search for other papers by Mauro Papotti in
Google Scholar
PubMed
Search for other papers by Marco Volante in
Google Scholar
PubMed
Search for other papers by Edda Vignali in
Google Scholar
PubMed
Search for other papers by Federica Saponaro in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
+ No WT WT 15 Alive with disease 5 12 M 20 15.0 1000 + No c.343G>T exon 4 (G) b E115X <5 Alive free of disease 23 (B) Patients without local invasion/recurrence and/or metastases ( n =10) d 14 F 76 13.4 410 + No WT WT 10 Alive free of disease 7 16 F
National Institute of Endocrinology CI Parhon, Bucharest, Romania
Search for other papers by Sofia Maria Lider Burciulescu in
Google Scholar
PubMed
National Institute of Endocrinology CI Parhon, Bucharest, Romania
Search for other papers by Monica Livia Gheorghiu in
Google Scholar
PubMed
Search for other papers by Andrei Muresan in
Google Scholar
PubMed
National Institute of Endocrinology CI Parhon, Bucharest, Romania
Search for other papers by Iuliana Gherlan in
Google Scholar
PubMed
Search for other papers by Attila Patocs in
Google Scholar
PubMed
National Institute of Endocrinology CI Parhon, Bucharest, Romania
Search for other papers by Corin Badiu in
Google Scholar
PubMed
free metanephrines ( n = 10–90 pg/mL); Mt, metastatic; MTC, medullary thyroid carcinoma; NA, not available; NMN, plasma free normetanephrines ( n = 20–200 pg/mL); O, open surgery; PHPTH, primary hyperparathyroidism; R, tumor recurrence; S
Search for other papers by C Chiapponi in
Google Scholar
PubMed
Search for other papers by H Alakus in
Google Scholar
PubMed
Search for other papers by M Faust in
Google Scholar
PubMed
Search for other papers by A M Schultheis in
Google Scholar
PubMed
Search for other papers by J Rosenbrock in
Google Scholar
PubMed
Search for other papers by M Schmidt in
Google Scholar
PubMed
a contemplated option in the ETA and ATA Guidelines ( 8 , 11 ). It has been found to be associated with improved local disease control and a longer progression-free survival time in few studies ( 12 , 13 ). However, evidence is still poor, and its
Search for other papers by Qi Zhang in
Google Scholar
PubMed
Search for other papers by Hongshan Wang in
Google Scholar
PubMed
Search for other papers by Yanhong Xie in
Google Scholar
PubMed
Search for other papers by Suming Huang in
Google Scholar
PubMed
Search for other papers by Ke Chen in
Google Scholar
PubMed
Search for other papers by Botian Ye in
Google Scholar
PubMed
Search for other papers by Yupeng Yang in
Google Scholar
PubMed
Search for other papers by Jie Sun in
Google Scholar
PubMed
Search for other papers by Hongyong He in
Google Scholar
PubMed
Search for other papers by Fenglin Liu in
Google Scholar
PubMed
Search for other papers by Zhenbin Shen in
Google Scholar
PubMed
Search for other papers by Weidong Chen in
Google Scholar
PubMed
Search for other papers by Kuntang Shen in
Google Scholar
PubMed
Search for other papers by Yuan Ji in
Google Scholar
PubMed
Search for other papers by Yihong Sun in
Google Scholar
PubMed
were performed by χ 2 -test or Mann–Whitney U- test. Overall survival (OS)/disease-free survival (DFS) was calculated from the date of surgical intervention until the date of the last contact or date of death/recurrence. Survivals were analyzed by
Search for other papers by Chan Sub Park in
Google Scholar
PubMed
Search for other papers by Jihye Choi in
Google Scholar
PubMed
Search for other papers by Min-Ki Seong in
Google Scholar
PubMed
Search for other papers by Sung-Eun Hong in
Google Scholar
PubMed
Search for other papers by Jae-Sung Kim in
Google Scholar
PubMed
Search for other papers by In-Chul Park in
Google Scholar
PubMed
Search for other papers by Hyesil Seol in
Google Scholar
PubMed
Search for other papers by Woo Chul Noh in
Google Scholar
PubMed
Search for other papers by Hyun-Ah Kim in
Google Scholar
PubMed
survival was defined as the time from diagnosis to the first event ending disease-free survival including locoregional recurrence, distant relapse, contralateral breast cancer, other primary cancer or death from any other cause. Survival analysis was
Search for other papers by Danuta Gąsior-Perczak in
Google Scholar
PubMed
Search for other papers by Iwona Pałyga in
Google Scholar
PubMed
Search for other papers by Monika Szymonek in
Google Scholar
PubMed
Search for other papers by Artur Kowalik in
Google Scholar
PubMed
Search for other papers by Agnieszka Walczyk in
Google Scholar
PubMed
Search for other papers by Janusz Kopczyński in
Google Scholar
PubMed
Search for other papers by Katarzyna Lizis-Kolus in
Google Scholar
PubMed
Search for other papers by Anna Słuszniak in
Google Scholar
PubMed
Search for other papers by Janusz Słuszniak in
Google Scholar
PubMed
Search for other papers by Tomasz Łopatyński in
Google Scholar
PubMed
Search for other papers by Ryszard Mężyk in
Google Scholar
PubMed
The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Stanisław Góźdź in
Google Scholar
PubMed
The Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Aldona Kowalska in
Google Scholar
PubMed
the number of new cases mostly affects low-stage papillary thyroid cancer (PTC), which responds well to treatment and has a low risk of recurrence ( 5 , 6 ). These epidemiological changes modified the approach to treatment and monitoring of DTC. In